Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 53
- Registration Number
- NCT00771329
- Locations
- 🇷🇺
Research Centre, Yaroslavl, Russian Federation
🇺🇸Research Site, Oklahoma City, Oklahoma, United States
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
Phase 4
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Biogen
- Registration Number
- NCT00771043
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 37
- Registration Number
- NCT00746941
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT00745316
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00744679
- Locations
- 🇺🇸
Research Site, Latham, New York, United States
Administration of BIIB028 to Subjects With Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 43
- Registration Number
- NCT00725933
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 420
- Registration Number
- NCT00709865
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
Terminated
- Conditions
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 87
- Registration Number
- NCT00707512
- Locations
- 🇵🇷
Research site, San Juan, Puerto Rico
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
Completed
- Conditions
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2012-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1000
- Registration Number
- NCT00675883
- Locations
- 🇨🇦
University Hospital, London Health Sciences Centre, London, Ontario, Canada
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 6
- Registration Number
- NCT00675428
- Locations
- 🇺🇸
Research Center, Rochester, Minnesota, United States
© Copyright 2024. All Rights Reserved by MedPath